Antagonistic interaction between Wnt and Notch activity modulates the regenerative capacity of a zebrafish fibrotic liver model

Mianbo Huang, Angela Chang, Minna Choi, David Zhou, Frank A. Anania, Chong Hyun Shin – 4 July 2014 – In chronic liver failure patients with sustained fibrosis, excessive accumulation of extracellular matrix proteins substantially dampens the regenerative capacity of the hepatocytes, resulting in poor prognosis and high mortality. Currently, the mechanisms and the strategies of inducing endogenous cellular sources such as hepatic progenitor cells (HPCs) to regenerate hepatocytes in various contexts of fibrogenic stimuli remain elusive.

Earlier presentation and application of curative treatments in hepatocellular carcinoma

Susanna V. Ulahannan, Austin G. Duffy, Timothy S. McNeel, Jonathan K. Kish, Lois A. Dickie, Osama E. Rahma, Katherine A. McGlynn, Tim F. Greten, Sean F. Altekruse – 4 July 2014 – The purpose of the study was to assess the use of curative therapies for hepatocellular carcinoma (HCC) in the population. HCC treatment patterns were examined in Surveillance, Epidemiology, and End Results (SEER) 18 registries (28% of U.S.).

Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study

Eleonora Scorletti, Lokpal Bhatia, Keith G. McCormick, Geraldine F. Clough, Kathryn Nash, Leanne Hodson, Helen E. Moyses, Philip C. Calder, Christopher D. Byrne, on behalf of the WELCOME Study Investigators – 4 July 2014 – There is no licensed treatment for nonalcoholic fatty liver disease (NAFLD), a condition that increases risk of chronic liver disease, type 2 diabetes, and cardiovascular disease.

Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial

Masatoshi Kudo, Guohong Han, Richard S. Finn, Ronnie T.P. Poon, Jean‐Frederic Blanc, Lunan Yan, Jijin Yang, Ligong Lu, Won‐Young Tak, Xiaoping Yu, Joon‐Hyeok Lee, Shi‐Ming Lin, Changping Wu, Tawesak Tanwandee, Guoliang Shao, Ian B. Walters, Christine Dela Cruz, Valerie Poulart, Jian‐Hua Wang – 4 July 2014 – Transarterial chemoembolization (TACE) is the current standard of treatment for unresectable intermediate‐stage hepatocellular carcinoma (HCC).

The transrepressive activity of peroxisome proliferator‐activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice

Michal Pawlak, Eric Baugé, William Bourguet, Karolien Bosscher, Fanny Lalloyer, Anne Tailleux, Corinna Lebherz, Philippe Lefebvre, Bart Staels – 4 July 2014 – Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and strongly associated with central obesity, dyslipidemia, and insulin resistance.

Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: A meta‐analysis

Mónica García‐Álvarez, Daniel Pineda‐Tenor, María A. Jiménez‐Sousa, Amanda Fernández‐Rodríguez, María Guzmán‐Fulgencio, Salvador Resino – 27 June 2014 – There is growing evidence that vitamin D is related to chronic hepatitis C (CHC) pathogenicity. We analyzed the relationship of vitamin D status with advanced liver fibrosis (ALF) in CHC treatment‐naïve patients and sustained virologic response (SVR) in CHC patients on pegylated interferon alpha plus ribavirin (pegIFNα/ribavirin) therapy.

Impact of broader sharing on the transport time for deceased donor livers

Sommer E. Gentry, Eric K. H. Chow, Corey E. Wickliffe, Allan B. Massie, Tabitha Leighton, Dorry L. Segev – 27 June 2014 – Recent allocation policy changes have increased the sharing of deceased donor livers across local boundaries, and sharing even broader than this has been proposed as a remedy for persistent geographic disparities in liver transplantation. It is possible that broader sharing may increase cold ischemia times (CITs) and thus harm recipients.

Subscribe to